Novacor SASU

by Mary Thompson Editor’s Note: The following article is based on Medtech Insight’s March 2007 report, Current and Emerging Technologies for the Management of Heart Failure in the US (Report #A211.) H

Edwards is using a biotech-like dealmaking strategy to leverage its evolution as an advanced-stage heart disease company. But is there a future in selling primarily to cardiac surgeons? by Stephen Lev

If a new generation of implantable devices can function reliably for many years, they may offer CHF patients an alternative to heart transplantation and even arrest the progression of the disease. by

For congestive heart failure patients, the only cure today is a heart transplant. But Kriton Medical Inc. hopes to offer a new alternative to transplantation, with a miniature, completely implantab